JP7847777B2 - ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン - Google Patents

ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン

Info

Publication number
JP7847777B2
JP7847777B2 JP2022554062A JP2022554062A JP7847777B2 JP 7847777 B2 JP7847777 B2 JP 7847777B2 JP 2022554062 A JP2022554062 A JP 2022554062A JP 2022554062 A JP2022554062 A JP 2022554062A JP 7847777 B2 JP7847777 B2 JP 7847777B2
Authority
JP
Japan
Prior art keywords
peptide
present
amino acid
seq
peptides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022554062A
Other languages
English (en)
Japanese (ja)
Other versions
JPWO2022071435A1 (https=
JPWO2022071435A5 (https=
Inventor
哲郎 引地
一馬 清谷
祐輔 中村
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cancer Precision Medicine
Original Assignee
Cancer Precision Medicine
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/JP2021/017159 external-priority patent/WO2022070496A1/ja
Application filed by Cancer Precision Medicine filed Critical Cancer Precision Medicine
Publication of JPWO2022071435A1 publication Critical patent/JPWO2022071435A1/ja
Publication of JPWO2022071435A5 publication Critical patent/JPWO2022071435A5/ja
Application granted granted Critical
Publication of JP7847777B2 publication Critical patent/JP7847777B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/165—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/215—Coronaviridae, e.g. avian infectious bronchitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/46—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—RNA viruses
    • C07K16/102—Coronaviridae (F)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C12N5/0638—Cytotoxic T lymphocytes [CTL] or lymphokine activated killer cells [LAK]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/02—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms
    • C12Q1/025—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving viable microorganisms for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Veterinary Medicine (AREA)
  • Virology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Communicable Diseases (AREA)
  • Biomedical Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Peptides Or Proteins (AREA)
JP2022554062A 2020-09-30 2021-09-29 ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン Active JP7847777B2 (ja)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
JP2020164630 2020-09-30
JP2020164630 2020-09-30
JPPCT/JP2021/017159 2021-04-30
PCT/JP2021/017159 WO2022070496A1 (ja) 2020-09-30 2021-04-30 ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン
US202163236927P 2021-08-25 2021-08-25
US63/236,927 2021-08-25
PCT/JP2021/035967 WO2022071435A1 (ja) 2020-09-30 2021-09-29 ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン

Publications (3)

Publication Number Publication Date
JPWO2022071435A1 JPWO2022071435A1 (https=) 2022-04-07
JPWO2022071435A5 JPWO2022071435A5 (https=) 2024-10-04
JP7847777B2 true JP7847777B2 (ja) 2026-04-20

Family

ID=80951674

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022554062A Active JP7847777B2 (ja) 2020-09-30 2021-09-29 ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン

Country Status (3)

Country Link
US (1) US20230357328A1 (https=)
JP (1) JP7847777B2 (https=)
WO (1) WO2022071435A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7598538B2 (ja) * 2021-01-29 2024-12-12 東亞合成株式会社 ＳＡＲＳ－ＣｏＶ－２由来のアミノ酸配列およびその利用

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111440229B (zh) * 2020-04-13 2021-08-03 中国人民解放军军事科学院军事医学研究院 新型冠状病毒t细胞表位及其应用

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Antibodies，2020年07月16日，doi:10.3390/antib9030033

Also Published As

Publication number Publication date
WO2022071435A1 (ja) 2022-04-07
JPWO2022071435A1 (https=) 2022-04-07
US20230357328A1 (en) 2023-11-09

Similar Documents

Publication Publication Date Title
WO2022070496A1 (ja) ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン
JP6518921B2 (ja) Ｔｈ１細胞のＩＭＰ−３エピトープペプチドおよびこれを含有するワクチン
JP7070945B2 (ja) Ｋｏｃ１由来ペプチドおよびそれを含むワクチン
AU2020201216B2 (en) URLC10-derived peptide and vaccine containing same
US12195559B2 (en) CDCA1-derived peptide and vaccine containing same
US10676508B2 (en) DEPDC1-derived peptide and vaccine containing same
US20240067679A1 (en) Sars-cov-2 protein-derived peptide and vaccine containing same
AU2016335731A1 (en) FOXM1-derived peptide, and vaccine including same
AU2020202681B2 (en) CDCA1-derived peptide and vaccine containing same
JP7847777B2 (ja) ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン
WO2022149295A1 (ja) ＳＡＲＳ－ＣｏＶ－２蛋白由来ペプチドおよびそれを含むワクチン
TW202604933A (zh) 源自SARS-CoV-2蛋白之胜肽及含其之疫苗
JP6857909B2 (ja) Ｍｐｈｏｓｐｈ１由来ペプチドおよびそれを含むワクチン
AU2021418202A1 (en) SARS-CoV-2 PROTEIN-DERIVED PEPTIDE AND VACCINE CONTAINING SAME
JP2017042047A (ja) Ｖｅｇｆｒ２由来ペプチドおよびそれを含むワクチン

Legal Events

Date Code Title Description
A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A801

Effective date: 20230322

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20230322

A80 Written request to apply exceptions to lack of novelty of invention

Free format text: JAPANESE INTERMEDIATE CODE: A80

Effective date: 20230322

RD04 Notification of resignation of power of attorney

Free format text: JAPANESE INTERMEDIATE CODE: A7424

Effective date: 20240424

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20240926

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20240926

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250908

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251106

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20260224

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20260325

R150 Certificate of patent or registration of utility model

Ref document number: 7847777

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150